Trial NCT02961374

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

This phase II trial studies the side effects of erlotinib hydrochloride and how well it works
in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of
developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.

Intervention

Erlotinib, Erlotinib Hydrochloride

Condition

APC Gene Mutation, Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis

Investigators

See list of participating sites